Department of Applied Biochemistry, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, Hachioji, Tokyo, Japan.
Laboratory of Pharmacology, School of Pharmacy, Josai University, Sakado, Saitama, Japan.
Invest Ophthalmol Vis Sci. 2021 Oct 4;62(13):23. doi: 10.1167/iovs.62.13.23.
Optic nerve damage leads to impairment of visual functions. We previously demonstrated that apolipoprotein E-containing lipoproteins (E-LPs) protect retinal ganglion cells (RGCs) from degeneration in a glaucoma model of glutamate/aspartate transporter-deficient mice. This study aimed to determine whether E-LPs protect RGCs from N-methyl-D-aspartate (NMDA)-induced excitotoxicity, and to investigate the details of an indirect neuroprotective mechanism of E-LPs by reducing α2-macroglobulin, which interferes with the neuroprotective effect of E-LPs, in Müller glia.
Excitotoxicity was caused by intravitreal injection of NMDA, and then retinae were subjected to immunoblotting or quantitative reverse transcription-PCR. Primary cultures of mouse mixed retinal cells and mouse Müller glia were used for evaluating the effects of E-LPs on the expression of α2-macroglobulin.
Intravitreal injection of E-LPs protected the optic nerve from degeneration and attenuated the increase in α2-macroglobulin in aqueous humor and retina of rats. E-LPs directly decreased the expression and secretion of α2-macroglobulin in primary cultures of Müller glia; this decrease in production of α2-macroglobulin was blocked by knockdown of the low-density lipoprotein receptor-related protein 1 (LRP1) with small interfering RNA. E-LPs promoted the phosphorylation of STAT3, whereas Stattic, an inhibitor of STAT3, restored the expression of α2-macroglobulin decreased by E-LPs.
In addition to our previous findings of the protection of RGCs by E-LPs, the new observations in Müller glia indicate that a reduction of the intraocular α2-macroglobulin, regulated by the E-LP-LRP1-STAT3 pathway, might be an additional protective mechanism against excitotoxicity in the retina.
视神经损伤导致视觉功能障碍。我们之前的研究表明,载脂蛋白 E 脂蛋白(E-LP)可保护谷氨酸/天冬氨酸转运体缺陷型小鼠青光眼模型中的视网膜神经节细胞(RGC)免于变性。本研究旨在确定 E-LP 是否可保护 RGC 免受 N-甲基-D-天冬氨酸(NMDA)诱导的兴奋性毒性,并通过减少α2-巨球蛋白(干扰 E-LP 的神经保护作用)来研究 E-LP 的间接神经保护机制的详细信息,在 Müller 胶质细胞中。
通过玻璃体内注射 NMDA 引起兴奋性毒性,然后对视网膜进行免疫印迹或定量逆转录 PCR。使用小鼠混合视网膜细胞和小鼠 Müller 胶质细胞的原代培养物来评估 E-LP 对α2-巨球蛋白表达的影响。
玻璃体内注射 E-LP 可保护视神经免于变性,并减轻 NMDA 注射大鼠房水和视网膜中α2-巨球蛋白的增加。E-LP 直接降低了原代培养的 Müller 胶质细胞中α2-巨球蛋白的表达和分泌;用小干扰 RNA 敲低低密度脂蛋白受体相关蛋白 1(LRP1)可阻断这种α2-巨球蛋白产生的减少。E-LP 促进了 STAT3 的磷酸化,而 STAT3 的抑制剂 Stattic 恢复了 E-LP 降低的α2-巨球蛋白的表达。
除了我们之前发现的 E-LP 对 RGC 的保护作用外,Müller 胶质细胞中的新发现表明,通过 E-LP-LRP1-STAT3 途径调节的眼内α2-巨球蛋白的减少可能是视网膜对抗兴奋性毒性的另一种保护机制。